<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943591</url>
  </required_header>
  <id_info>
    <org_study_id>CE13.092</org_study_id>
    <nct_id>NCT01943591</nct_id>
  </id_info>
  <brief_title>DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial</brief_title>
  <acronym>DELTA</acronym>
  <official_title>DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DePuy Synthes</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson Medical Companies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endovascular treatment with platinum coils is safe and effective in preventing rebleeding of
      intracranial aneurysms. Unfortunately, endovascular treatment of aneurysms with coils has
      been associated with incomplete occlusion at initial treatment (remnant) or at follow-up
      (recurrence). This in some studies has been as high as 20%. While many such aneurysm remnants
      or recurrences exhibit benign behavior, many require retreatment to prevent future
      hemorrhage.

      A recent randomized controlled trial of aneurysm coiling revealed that aneurysms between 2
      and 9.9 mm diameter were more likely to have an improved angiographic and composite clinical
      outcome when treated with hydrogel-coated coils, an improvement inferred to result from
      higher packing density afforded by hydrogel expansion(1). The use of hydrogel coils is
      associated with technical difficulties related to expansion and limited time for deployment.
      The investigators theorize that similar results could be achieved by using more voluminous
      bare platinum coils, leading to improved packing density compared to smaller caliber coils,
      and thus result in lower incidence of remnants or residuals. The relationship between packing
      densities and composite clinical endpoints having never been shown in a robust fashion, the
      investigators therefore propose a randomized clinical trial opposing coiling with soft
      15-caliber coils to 10-caliber bare platinum coils in aneurysms varying in size from 3 to 9.9
      mm.

      To test the hypothesis that 15-caliber coiling systems are superior to standard 10-caliber
      coils in achieving better composite outcomes, the investigators propose the DELTA trial: Does
      Embolization with Larger coils lead to better Treatment of Aneurysms trial, a randomized
      controlled blinded trial with 2 subgroups of 282 patients each, 564 total:

      Subgroup 1: Coiled with a maximum proportion of 15-caliber coils as conditions allow Subgroup
      2: Coiled with 10-caliber coils.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 13, 2013</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Recurrence of Lesion or Presence of Residual Aneurysm</measure>
    <time_frame>1 year</time_frame>
    <description>Major radiographic recurrence of the lesion or the presence of a 'residual aneurysm' as judged by core lab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemorrhage During the Follow-up Period</measure>
    <time_frame>Within 1 year following coiling</time_frame>
    <description>Post-treatment hemorrhage experienced during follow-up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retreatment of the Same Lesion by Endovascular or Surgical Means</measure>
    <time_frame>Within 1 year following coiling</time_frame>
    <description>Retreatment of the same lesion by endovascular or surgical means during the follow-up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Initial Treatment Failure</measure>
    <time_frame>Within 1 year following coiling</time_frame>
    <description>Inability to treat aneurysm, either because access to aneurysm is difficult or technical issues.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Related Morbidity</measure>
    <time_frame>Within 1 year following coiling</time_frame>
    <description>Morbidity that precludes follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Related Mortality</measure>
    <time_frame>Within 1 year following coiling</time_frame>
    <description>Mortality that precludes follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Packing Density</measure>
    <time_frame>within the first 3 days after coiling</time_frame>
    <description>Packing density with the number of coils implanted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Serious Adverse Events (SAEs)</measure>
    <time_frame>Within 6 months following coiling</time_frame>
    <description>Procedural-related serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score (mRS) Greater Than 2</measure>
    <time_frame>at 1 year follow-up</time_frame>
    <description>Modified Rankin Score (mRS) that is greater than 2 at 1 year follow-up (or at last follow-up, if applicable). Minimum = 0 (no symptoms), maximum = 6 (Deceased).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <arm_group>
    <arm_group_label>15-caliber platinum coils</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovascular embolization coiling using 15-caliber platinum coils</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-caliber coils</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endovascular embolization coiling using standard 10-caliber platinum coils</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils</intervention_name>
    <description>Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
    <arm_group_label>10-caliber coils</arm_group_label>
    <arm_group_label>15-caliber platinum coils</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one ruptured or unruptured aneurysms with a dimension ≥ 10 mm (longest axis)

          -  for ruptured lesions, patients should be in World Federation of Neurosurgical
             Societies (WFNS) grade &lt; IV.

          -  The anatomy of the lesion is such that endovascular treatment is possible with both
             types of coils (not necessarily certain or probable)

          -  Patient is 18 or older

          -  Life expectancy is more than 2 years (able to complete follow-up)

        Exclusion Criteria:

          -  Patients with planned treatment of an associated cerebral arteriovenous malformations

          -  When parent vessel occlusion, without simultaneous endosaccular coiling of the
             aneurysm, is the primary intent of the procedure

          -  Any absolute contraindication to endovascular treatment, angiography, or anaesthesia
             such as severe allergies to contrast or medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Raymond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center (SUNY)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University, Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>White PM, Lewis SC, Gholkar A, Sellar RJ, Nahser H, Cognard C, Forrester L, Wardlaw JM; HELPS trial collaborators. Hydrogel-coated coils versus bare platinum coils for the endovascular treatment of intracranial aneurysms (HELPS): a randomised controlled trial. Lancet. 2011 May 14;377(9778):1655-62. doi: 10.1016/S0140-6736(11)60408-X.</citation>
    <PMID>21571149</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <results_first_submitted>January 9, 2020</results_first_submitted>
  <results_first_submitted_qc>January 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment trial</keyword>
  <keyword>cerebral aneurysm</keyword>
  <keyword>randomized</keyword>
  <keyword>coils</keyword>
  <keyword>endovascular</keyword>
  <keyword>Aneurysm</keyword>
  <keyword>Intracranial Aneurysm</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Intracranial Arterial Diseases</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT01943591/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: November 2013 to june 2017, from 12 centres in Canada and U.S.A.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>15-caliber Platinum Coils</title>
          <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
        </group>
        <group group_id="P2">
          <title>10-caliber Coils</title>
          <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>15-caliber Platinum Coils</title>
          <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
        </group>
        <group group_id="B2">
          <title>10-caliber Coils</title>
          <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="106"/>
                    <count group_id="B3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="10"/>
                    <measurement group_id="B2" value="57" spread="11"/>
                    <measurement group_id="B3" value="57" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="106"/>
                    <count group_id="B3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Recurrence of Lesion or Presence of Residual Aneurysm</title>
        <description>Major radiographic recurrence of the lesion or the presence of a 'residual aneurysm' as judged by core lab</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Recurrence of Lesion or Presence of Residual Aneurysm</title>
          <description>Major radiographic recurrence of the lesion or the presence of a 'residual aneurysm' as judged by core lab</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemorrhage During the Follow-up Period</title>
        <description>Post-treatment hemorrhage experienced during follow-up period.</description>
        <time_frame>Within 1 year following coiling</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemorrhage During the Follow-up Period</title>
          <description>Post-treatment hemorrhage experienced during follow-up period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retreatment of the Same Lesion by Endovascular or Surgical Means</title>
        <description>Retreatment of the same lesion by endovascular or surgical means during the follow-up period</description>
        <time_frame>Within 1 year following coiling</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Retreatment of the Same Lesion by Endovascular or Surgical Means</title>
          <description>Retreatment of the same lesion by endovascular or surgical means during the follow-up period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Initial Treatment Failure</title>
        <description>Inability to treat aneurysm, either because access to aneurysm is difficult or technical issues.</description>
        <time_frame>Within 1 year following coiling</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Treatment Failure</title>
          <description>Inability to treat aneurysm, either because access to aneurysm is difficult or technical issues.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Related Morbidity</title>
        <description>Morbidity that precludes follow up</description>
        <time_frame>Within 1 year following coiling</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Related Morbidity</title>
          <description>Morbidity that precludes follow up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Packing Density</title>
        <description>Packing density with the number of coils implanted</description>
        <time_frame>within the first 3 days after coiling</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Packing Density</title>
          <description>Packing density with the number of coils implanted</description>
          <units>percentage of packing density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="22.2"/>
                    <measurement group_id="O2" value="26.9" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Serious Adverse Events (SAEs)</title>
        <description>Procedural-related serious adverse events</description>
        <time_frame>Within 6 months following coiling</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Serious Adverse Events (SAEs)</title>
          <description>Procedural-related serious adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Rankin Score (mRS) Greater Than 2</title>
        <description>Modified Rankin Score (mRS) that is greater than 2 at 1 year follow-up (or at last follow-up, if applicable). Minimum = 0 (no symptoms), maximum = 6 (Deceased).</description>
        <time_frame>at 1 year follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Score (mRS) Greater Than 2</title>
          <description>Modified Rankin Score (mRS) that is greater than 2 at 1 year follow-up (or at last follow-up, if applicable). Minimum = 0 (no symptoms), maximum = 6 (Deceased).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Related Mortality</title>
        <description>Mortality that precludes follow up</description>
        <time_frame>Within 1 year following coiling</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15-caliber Platinum Coils</title>
            <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
          <group group_id="O2">
            <title>10-caliber Coils</title>
            <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
          </group>
        </group_list>
        <measure>
          <title>Related Mortality</title>
          <description>Mortality that precludes follow up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events are reported for a time period of within 1 year post aneurysm treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>15-caliber Platinum Coils</title>
          <description>Endovascular embolization coiling using 15-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
        </group>
        <group group_id="E2">
          <title>10-caliber Coils</title>
          <description>Endovascular embolization coiling using standard 10-caliber platinum coils
Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Event unrelated to aneurysm or its treatment causing mortality</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aneurysm rupture during procedure causing Mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Aneurysm rupture during procedure causing morbidity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke, periprocedure causing mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Stroke, related to SAH at presentation causing mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage during follow-up causing mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Stroke, causing morbidity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SAH during follow-up, causing morbidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage (aneurysm rupture during procedure)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Subarachnoid Hemorrhage during follow-up</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than 12 months after the conclusion of the study at all sites.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial was stopped before target number of patients were recruited due to funding being interrupted.
Premature interruption of the trial does not allow a conclusion regarding the primary hypothesis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jean Raymond</name_or_title>
      <organization>Centre hospitalier de l'Université de Montréal Research Centre</organization>
      <phone>514-890-8000 ext 27235</phone>
      <email>jraymond.nri@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

